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Determination of the
Incidence of Tuberculosis
in Low-Income Countries
To the Editor—We read with interest
the report by The Antiretroviral Therapy
in Low-Income Countries Collaboration
of the International epidemiological Da-
tabases to Evaluate AIDS (IeDEA) andThe
ART Cohort Collaboration on tubercu-
losis (TB) after initiation of antiretroviral
therapy in low-income and high-income
countries [1]. The authors do notmention
the number of patients who were already
receiving treatment for TB when the an-
tiretroviral therapy was started (were the
data not available?). However, they do
mention that programs in lower-income
countries routinely screened patients for
TB before they commenced HAART. It is
unclear to us whether patients being given
treatment for TB at the start of HAART
were included in the analysis. We propose
that they should have been excluded from
the study population if the aim of the
study was to determine the incidence of
TB and to compare the incidence rate-
ratios for new TB infections. Indeed, in
contrast to in high-income countries, in
low-income countries, TB is one of the
main reasons to initiate HAART. In Ma-
lawi, for example, from July through Sep-
tember 2005, 12% of the patients who
started HAART did so because of TB [2].
During treatment for TB, by definition
these patients cannot develop a new TB
infection. We suppose that, if this ap-
proach were taken, the conclusions of the
report would remain the same, but the
calulations may change slightly. If the
number of patients not receiving treat-
ment for TB who started HAART is used
as the denominator, the real incidence of
TB in low-income countries will be even
higher, particularly soon after the initia-
tion of HAART.
Acknowledgments
Potential conflict of interest. R.C. and S.C.:
no conflicts
Robert Colebunders1,2
and Se´verine Caluwaerts1
1Institute of Tropical Medicine and 2University of
Antwerp, Antwerp, Belgium
References
1. The Antiretroviral Therapy in Low-Income
Countries Collaboration of the International
epidemiological Databases to Evaluate AIDS
(IeDEA) and The ART Cohort Collaboration.
Tuberculosis after initiation of antiretroviral
therapy in low-income and high-income coun-
tries. Clin Infect Dis 2007; 45:1518–21.
2. Makombe SD, Harries AD, Yu JK, et al. Out-
comes of tuberculosis patients who start anti-
retroviral therapy under routine programme
conditions in Malawi. Int J Tuberc Lung Dis
2007; 11:412–6.
Reprints or correspondence: Dr. Robert Colebunders, Institute
of Tropical Medicine, Nationalestraat 155, Antwerp, Belgium
(bcoleb@itg.be).
Clinical Infectious Diseases 2008; 46:1482
 2008 by the Infectious Diseases Society of America. All
rights reserved. 1058-4838/2008/4609-0031$15.00
DOI: 10.1086/587182
Reply to Colebunders
and Caluwaerts
To the Editor—We thank Colebunders
and Caluwaerts [1] for their interest in the
recent analysis by The AntiretroviralTher-
apy in Low-Income Countries Collabo-
ration of the International epidemiological
Databases to Evaluate AIDS (IeDEA) and
The ARTCohort Collaboration [2]. In this
collaborative study, we compared the in-
cidence rates of tuberculosis (TB) among
patients receiving HAART in low-income
and high-income countries. Colebunders
and Caluwaerts ask whether the analysis
included patients who were receiving
treatment for TB at the start of HAART
and argue that, if so, this might have bi-
ased the incidence rates of TB downward
in lower-income countries andmight have
distorted the incidence-rate ratios during
the firs year of HAART.
As Caluwaerts and Colebunders [1]
suspected, data on treatment for TB at the
time of initiation of HAART were not
available for all the cohorts from low-in-
come countries. But note that, as we
pointed out in our report [2], the main
objective of the analysis was not to esti-
mate absolute rates but was to compare
relative changes in rates of TB during the
firs year of HAART in low-income and
high-income settings. The incidence rates
obtained in such an analysis of data from
15 different sites were a weighted average
of site-specifi rates, influence by varia-
tion in background rates and diagnostic
procedures, and are not applicable to any
specifi setting.
We repeated analyses for 9 low-income
cohorts with data on previous treatment
for TB, including 2050 patients who were
not receiving treatment whenHAARTwas
started. Among these patients, the inci-
dence of TB in the firs year of HAART
was 8.8 cases per 100 person-years (95%
CI, 7.5–10.3 cases per 100 person-years),
which is slightly higher than the 7.4 cases
per 100 person-years (95% CI, 6.6–8.4
cases per 100 person-years) reported in the
previously published analysis [2]. As pre-
dicted by Caluwaerts and Colebunders
[1], this difference was more pronounced
during the firs 3 months of treatment:
13.9 cases per 100 person-years (95% CI,
11.0–17.6 cases per 100 person-years) in
this analysis, compared with 10.7 cases per
100 person-years (95% CI, 8.9–12.9 cases
per 100 person-years) in the original anal-
ysis. The decrease in the incidence rate
during the firs year of HAART was, how-
ever, similar for the 2 analyses. Compared
with the rate for months 1–3, the rate ratio
was 0.65 (95% CI, 0.44–0.96) for months
4–6 and was 0.39 (95% CI, 0.27–0.58) for
months 7–12. The corresponding ratios
from the original analysis were 0.70 (95%
CI, 0.52–0.94) and 0.48 (95% CI, 0.36–
0.64), respectively. Interestingly, the inci-
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Table 1. The association of vanco-
mycin treatment group and OR of
mortality.
Treatment
group
OR
Univariate Multivariable
VMIC 1.0 1.0 1.0
VMIC 1.5 1.9 (0.8–5) 2.9 (0.9–9.4)
VMIC 2.0 2.6 (0.9–8) 6.4 (1.7–24.3)
NA 2.3 (0.9–6) 3.6 (1.2–10.9)
NOTE. Data are summarized from the arti-
cle by Soriano et al. [1]. NA, receipt of inappro-
priate empirical therapy; VMIC 1.0, receipt of
empirical vancomycin and an isolate with a van-
comycin MIC of 1 mg/mL; VMIC 1.5, receipt of
empirical vancomycin and an isolate with a van-
comycin MIC of 1.5 mg/mL; VMIC 2.0, receipt
of empirical vancomycin and an isolate with a
vancomycin MIC of 2 mg/mL.
dence-rate ratios from this analysis are
somewhat closer to those reported for the
high-income cohorts in the original anal-
ysis [2]. The sensitivity analysis prompted
by the letter from Caluwaerts and Cole-
bunders thus strengthens our conclusions
that the reduction in rates of TB during
the firs year of HAART is similar in low-
income and high-income settings.
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Shock as a Covariate in a
Study of Treatment of
Methicillin-Resistant
Staphylococcus aureus
Bacteremia
To the Editor—Although the recently
published article by Soriano et al. [1] com-
ments on an important and interesting
topic, I feel that the article has significan
methodological flaw that have an impact
on the conclusions made by the authors.
Specificall , there are large and important
differences between theOR estimates from
the multivariate and univariate analyses
for the association of mortality and van-
comycin treatment group (see table 1,
which summarizes the ORs presented by
Soriano et al. [1]). The authors placed
shock as a covariate in their multivariable
model. They give the rationalization that
this is a negative confounder of the as-
sociation between treatment group and
mortality.
I would argue, however, that shock
should not be in the model, because it is
on the causal pathway from treatment
group to death. Including this in the
model would generate OR estimates for
the association of treatment group and
mortality, which then are—theoretically—
independent of shock.
I am not sure how to interpret their
model in this context or the multivariable
OR they present. What is the reason to
include shock as a covariate?
It would be helpful to see a multivari-
ablemodel for the association of treatment
group and mortality without shock as a
covariate in the model. It would also be
helpful to see an assessment of the overall
statistical significanc of the treatment-
group effect in the model, in addition to
the individual OR by subgroup.
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Vancomycin Minimum
Inhibitory Concentration
as a Predictor of Mortality
in Methicillin-Resistant
Staphylococcus aureus
Bacteremia: A Second Look
To the Editor—We read with interest
the article by Soriano et al. [1] that de-
scribed vancomycin MIC as a predictor of
mortality in patients with methicillin-re-
sistant Staphylococcus aureus bacteremia.
The issue ofMIC “creep”was documented
elsewhere [2], and the conclusion that a
higherMIC is associated with an increased
risk of mortality is not surprising. In ad-
dition, the presence of shock associated
with methicillin-resistant Staphylococcus
aureus bacteremia was documented else-
where as a risk factor for mortality [3].
However, the negative associationbetween
the development of shock and vancomy-
cin MIC is extremely intriguing. Soriano
et al. [1] hypothesize that this relationship
could be attributed to a decrease in path-
ogenicity as resistance increases through a
variety of mechanisms. We offer an alter-
native explanation of the data and address
some concerns with the study by Soriano
et al. [1].
After examination of the absolute in-
cidence of patient characteristics, it is clear
that the development of shock is nega-
tively associated with vancomycin MIC
without adjustment for confounding var-
iables (for 1 mg/mL, 28.4%; for 1.5 mg/mL,
20.2%; for 2 mg/mL, 10.9%; ). ItPp .007
is also clear that heart failure occurred in
a significantl higher percentage of pa-
